pharma-and-clinical-pharmacy-congress-2016_posters

4 / 21

Notes:
Page 54
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Maria-Gabriela Perez-Guille, Clin Pharmacol Biopharm 2016, 5:4(Suppl)
Dexmedetomidine population pharmacokinetics, adverse reactions and their relationship with
blood levels in pediatric patients
Maria-Gabriela Perez-Guille
National Institute of Pediatrics, Mexico
Introduction: Dexmedetomidine (DXM) is α2-adrenergic drug used for sedation, analgesia and as a co-adjuvant in anesthesia,
in surgical procedures, radiology, and instrumentation in pediatrics. Bradycardia and hypotension have been described as the
main adverse reactions. This drug is advantageous to have little effect on the respiratory system. Studies concerning DXM
pharmacokinetics in pediatric patients and their correlation with blood levels and adverse effects are still needed. In the present
work, population pharmacokinetics was used to analyze a sample of pediatric patients treated with DXM.
Objective: To describe DXM population pharmacokinetics in pediatric patients, to establish any possible correlation between
drug blood concentration and adverse effects.
Materials &Methods: The study included 32 pediatric patients (ASA I y II), 2.0 to 18 years-old, who underwent minor surgical
procedures and received DXM as per the inductor of anesthesia or as sedative, at a doses of 0.7 µg/kg of body weight in 20
minutes infusion, four blood samples were taken from each patient at different time intervals designated randomly and their
pharmacokinetic profile were constructed. Vitals were monitored throughout the entire procedure.
Results: No adverse effect was found. Concerning the level of sedation, all patients during surgery reached the Ramsay scale
6 and emerged to level 2. As per the pharmacokinetic parameter obtained in the study are consistent with those previously
reported in the literature.
Discussion: In this study, no adverse effect was found so we can conclude that the use of DXM is efficient and safe in children
and adolescents at a dose of 0.7 mg/kg of body weight.
Biography
Maria-Gabriela Perez-Guille has studied Medicine from the Universidad Nacional Autonoma de Mexico. She has 30 years of experience in conducting research
in the field of Clinical Pharmacology. She has been working at the National Institute of Pediatrics, Mexico as a Researcher in Medical Sciences, Level-D. She is
a Member of the Mexican National System of Researchers; Level-I. She has published 41 papers in the field of pharmacology. She is the Director of Medicine
students and residents and also a Pharmacology Professor for BSc and MSc students.